263 related articles for article (PubMed ID: 29132566)
21. Current approach and future perspective for ductal carcinoma in situ of the breast.
Kanbayashi C; Iwata H
Jpn J Clin Oncol; 2017 Aug; 47(8):671-677. PubMed ID: 28486668
[TBL] [Abstract][Full Text] [Related]
22. Analysis of active surveillance as a treatment modality in ductal carcinoma in situ.
Fan B; Pardo JA; Alapati A; Hopewood P; Mohammad Virk Z; James TA
Breast J; 2020 Jun; 26(6):1221-1226. PubMed ID: 31925857
[TBL] [Abstract][Full Text] [Related]
23. Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?
Punglia RS; Schnitt SJ; Weeks JC
J Natl Cancer Inst; 2013 Oct; 105(20):1527-33. PubMed ID: 24068769
[TBL] [Abstract][Full Text] [Related]
24. Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study.
Nickel B; McCaffery K; Houssami N; Jansen J; Saunders C; Spillane A; Rutherford C; Dixon A; Barratt A; Stuart K; Robertson G; Hersch J
Breast; 2020 Dec; 54():99-105. PubMed ID: 32971350
[TBL] [Abstract][Full Text] [Related]
25. Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis.
De Lorenzi F; Di Bella J; Maisonneuve P; Rotmensz N; Corso G; Orecchia R; Colleoni M; Mazzarol G; Rietjens M; Loschi P; Marcelli S; Veronesi P; Galimberti V
Eur J Surg Oncol; 2018 Jul; 44(7):957-962. PubMed ID: 29759643
[TBL] [Abstract][Full Text] [Related]
26. Advances and controversies in management of breast ductal carcinoma in situ (DCIS).
Farante G; Toesca A; Magnoni F; Lissidini G; Vila J; Mastropasqua M; Viale G; Penco S; Cassano E; Lazzeroni M; Bonanni B; Leonardi MC; Ripoll-Orts F; Curigliano G; Orecchia R; Galimberti V; Veronesi P
Eur J Surg Oncol; 2022 Apr; 48(4):736-741. PubMed ID: 34772587
[TBL] [Abstract][Full Text] [Related]
27. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
Delaloge S; Khan SA; Wesseling J; Whelan T
Lancet; 2024 Jun; 403(10445):2734-2746. PubMed ID: 38735296
[TBL] [Abstract][Full Text] [Related]
28. Current Therapeutic Approaches to DCIS.
Doke K; Butler S; Mitchell MP
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):279-291. PubMed ID: 30267199
[TBL] [Abstract][Full Text] [Related]
29. Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging Needs.
Nguyen DL; Greenwood HI; Rahbar H; Grimm LJ
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330503. PubMed ID: 38090808
[TBL] [Abstract][Full Text] [Related]
30. The role of clinical trials in changing therapy for ductal carcinoma in situ.
Wood WC
Ann Surg Oncol; 2004 Jan; 11(1 Suppl):24S-27S. PubMed ID: 15015706
[TBL] [Abstract][Full Text] [Related]
31. Actual management of ductal carcinoma in situ of the breast.
Maass N; Alkasi O; Bauer M; Jonat W; Souchon R; Meinhold-Heerlein I
Arch Gynecol Obstet; 2009 Nov; 280(5):699-705. PubMed ID: 19259692
[TBL] [Abstract][Full Text] [Related]
32. Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Mitchell KB; Kuerer H
Curr Oncol Rep; 2015 Nov; 17(11):48. PubMed ID: 26373411
[TBL] [Abstract][Full Text] [Related]
33. Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M; Lips EH; Thompson AM; Nik-Zainal S; Futreal A; Hwang ES; Verschuur E; Lane J; Jonkers J; Rea DW; Wesseling J;
Br J Cancer; 2019 Aug; 121(4):285-292. PubMed ID: 31285590
[TBL] [Abstract][Full Text] [Related]
34. Should low-risk DCIS lose the cancer label? An evidence review.
Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
[TBL] [Abstract][Full Text] [Related]
35. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
36. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Land S; Mamounas E; Dignam J; Fisher ER; Wolmark N
Semin Oncol; 2001 Aug; 28(4):400-18. PubMed ID: 11498833
[TBL] [Abstract][Full Text] [Related]
37. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy.
Mirza NQ; Vlastos G; Meric F; Sahin AA; Singletary SE; Newman LA; Kuerer HM; Ames FC; Ross MI; Feig BW; Pollock RE; Buchholz TA; McNeese MD; Strom EA; Hortobagyi GN; Hunt KK
Ann Surg Oncol; 2000 Oct; 7(9):656-64. PubMed ID: 11034242
[TBL] [Abstract][Full Text] [Related]
38. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma
Glencer AC; Miller PN; Greenwood H; Maldonado Rodas CK; Freimanis R; Basu A; Mukhtar RA; Brabham C; Kim P; Hwang ES; Rosenbluth JM; Hirst GL; Campbell MJ; Borowsky AD; Esserman LJ
Cancer Res Commun; 2022 Dec; 2(12):1579-1589. PubMed ID: 36970720
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.
Lazzeroni M; Dunn BK; Pruneri G; Jereczek-Fossa BA; Orecchia R; Bonanni B; DeCensi A
Cancer Treat Rev; 2017 Apr; 55():1-9. PubMed ID: 28262606
[TBL] [Abstract][Full Text] [Related]
40. Evidence map of ductal carcinoma in situ management options.
Bouskill K; Hempel S; Richardson A; Ganz PA; Baxi S; Zutshi R; Larkin J; Motala A; Miles JNV; Crandall CJ
Menopause; 2019 Nov; 26(11):1250-1258. PubMed ID: 31567868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
